Author Archives: urologyadmin

Comments: The HERO trial is an international, multicenter study comparing Relugolix (an oral androgen deprivation therapy agent given 120 mg orally, once daily) to leuprolide (22.5 mg injection, every 3 months) for 48 weeks. The primary end point of the study was the sustained suppression of testosterone to castrate levels, defined as testosterone less than […]

Comments: The US Food & Drug Administration on May 15, 2020, granted accelerated approval for the oral PARP inhibitor rucaparib for the treatment of patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic mCRPC who have been treated with androgen receptor (AR)–directed therapy and a taxane-based chemotherapy , based on objective tumor and prostate-specific antigen (PSA) […]